---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-036234"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T04:57:50.736718+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Celularity CMO Adrian Kilcoyne resigns effective August 6, 2024

## Summary
- Adrian Kilcoyne, EVP and Chief Medical Officer, resigns to pursue other opportunities.
- Resignation effective August 6, 2024; no successor announced.
- No disagreement with Celularity cited; departure unrelated to operations or policies.

## SEC filing metadata
- accession: 0001493152-24-036234
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315224036234/0001493152-24-036234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315224036234/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-036234
- JSON: https://secwatch.observer/filing/0001493152-24-036234.json
- Plain text: https://secwatch.observer/filing/0001493152-24-036234.txt

## Key facts
- Executive change
  Adrian Kilcoyne resigned as Executive Vice President and Chief Medical Officer at Celularity Inc.
  - Action: resigned
  - Role: Executive Vice President and Chief Medical Officer
  source text: Adrian Kilcoyne, M.D., M.P.H., M.B.A. of Celularity Inc., or Celularity, provided notice of resignation from his role as Executive Vice President and Chief Medical Officer, effective as of August 6, 2024, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000149315224036234/0001493152-24-036234-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.